A multi-stage malaria vaccine aims to:
• Attain higher efficacy by targeting multiple parasite stages
• decrease the risk of immune escape
• mitigate the effect of host heterogeneity that affect immune responses any of the antigens
• reduce the force of infection in the vaccinated community by including a transmission-blocking antigen
Through funding from EDCTP2 the Multi-Stage Malaria Vaccine Consortium aims to develop and demonstrate the efficacy of a multistage malaria vaccine containing pre-erythrocytic (R21/Matrix-M), Blood-stage (PfRH5) and transmission-blocking (Pfs25) components.